Table 2: Efficacy Results in Patients with RET Fusion-Positive Solid Tumors in Study LIBRETTO-001.
RETEVMO (n = 41) | |
---|---|
Overall Response Rate1 (95% CI) | 44% (28, 60) |
Complete response | 4.9% |
Partial response | 39% |
Duration of Response | |
Median in months (95% CI) | 24.5 (9.2, NE) |
% with ≥6 months2 | 67% |
Confirmed overall response rate assessed by BIRC.
Based on observed duration of response.
NE = not estimable
Source: U.S. product labeling, RETEVMO (selpercatinib)5